|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antisense oligodeoxynucleotides specific for sequences in mRNAs from the B-cell lymphoma/leukemia-2 (BCL2) gene were used to inhibit the growth in culture of a human leukemia cell line, 697.
|
2208117 |
1990 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The B-cell lymphoma/leukemia oncogene bcl-2 takes part in crucial regulatory events in B-cell maturation and differentiation.
|
1427749 |
1992 |
|
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These data confirm the cytogenetic observations that translocations involving the BCL2 locus in all forms of leukemia of mature B cells are rare, and limited to a minor subset of B-CLL.
|
8204892 |
1994 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The protective role of bcl-2 on cell death by HPR was investigated in HL60 as well as 697 pre-B leukemia and Jurkat T-acute lymphocytic leukemia (T-ALL) cells constitutively expressing high levels of bcl-2 proteins due to gene transfer manipulation.
|
7811993 |
1995 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The elevated levels of BCL-2 in cells that express AML1/ETO may prolong their life span and contribute to the development of t(8;21) leukemia.
|
8943060 |
1996 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Quantitation of bcl-2 oncogene in cultured lymphoma/leukemia cell lines and in primary leukemia B-cells by a highly sensitive RT-PCR method.
|
8647513 |
1996 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that human erythroleukemia (HEL) and K562, two leukemia cell lines that undergo erythroid differentiation do not express Bcl-2, but express Bcl-XL, a related protein that functions as an inhibitor of apoptosis.
|
8611710 |
1996 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
None of the high-risk features predictive of poor treatment outcome in childhood ALL, such as older age, high white blood cell (WBC) count, organomegaly, T-lineage immunophenotype, ability of leukemic cells to cause overt leukemia in severe combined immunodeficient (SCID) mice, presence of MLL-AF4, and BCR-ABL fusion transcripts were associated with high levels of BCL-2 expression.
|
9160683 |
1997 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Bcl-2 protein inhibits bufalin-induced apoptosis through inhibition of mitogen-activated protein kinase activation in human leukemia U937 cells.
|
9242431 |
1997 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Some forms of chemoresistance in leukemia may start from failure of tumour cells to successfully undergo apoptosis and Bcl-2 may play a role in this defect.
|
10554162 |
1999 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BCL-2 expression in childhood leukemia versus spontaneous apoptosis, drug induced apoptosis, and in vitro drug resistance.
|
10500808 |
1999 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that the acquisition of IFN-gamma-mediated autocrine survival signals, other than Bcl-2 or BCL-XL, might be important for the development of EBV-infected NK leukemia.
|
10233902 |
1999 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies of tumor suppressor genes and proto-oncogenes in the BCL2 family genes may unravel the mechanisms of leukemia cell progression and the development of drug resistance, leading to innovative therapies.
|
10500813 |
1999 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bcl-2 interferes with the execution phase, but not upstream events, in glucocorticoid-induced leukemia apoptosis.
|
9989821 |
1999 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bcl-2 oncogene (B cell lymphoma/leukemia-2) levels correlate with systemic lupus erythematosus disease activity.
|
10652595 |
2000 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It is also suggested that the suppression of apoptosis associated with enhanced bcl-2 expression and p53 accumulation increases the probability of developing leukemia in MDS, and that oncogenetic development might be different between MDS-derived AML and de novo AML.
|
10692673 |
2000 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The proportion of bcl-2 protein positive cells did not differ significantly among various leukemia subtypes, except for significant differences between p53-positive and p53-negative peripheral blood (p=0.0073) and bone marrow (p=0.0175) cells of B-CLL patients.
|
14689061 |
2003 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cell culture, tissue chemistry and flow cytometry were used to determine whether antisense bcl-2 oligodeoxynucleotides enhanced the sensitivity of leukemia cells to arsenic trioxide.
|
14642526 |
2003 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death.
|
12931228 |
2003 |
|
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
p53 and Bcl-2 protein accumulation and mutations have been found in a wide variety of cancers including different types of leukemia, with varying frequencies.
|
12375054 |
2003 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
RNAi is a functional pathway in human myeloid leukemia cell lines and combined RNAi of c-raf and bcl-2 genes may represent a novel approach to leukemia, providing a means to overcome the resistance to chemotherapeutic agents and ultimately to augment the efficacy of chemotherapy in myeloid leukemia.
|
12536201 |
2003 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of Bcl-2 plays a role in the development of drug resistance in leukemia and other apoptosis-prone tumors.
|
12631622 |
2003 |
|
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Translocation of the B-cell lymphoma/leukemia-2 ( bcl-2) gene was also examined.
|
15060790 |
2004 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Given that many human chronic lymphocytic leukemias overexpress TRAF1 and Bcl-2, our findings suggest that cooperation between Bcl-2 and TRAF pathways contributes to the development of this type of leukemia.
|
15545599 |
2004 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antiapoptotic BCL-2 is required for maintenance of a model leukemia.
|
15380515 |
2004 |